Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial

Capsule Summary: Astegolimab targeting of the IL-33/ST2 pathway reduces asthma exacerbations in severe asthma patients, highlighting the importance of IL-33 in driving non-Type 2-mediated pathways of inflammation.

Source: Journal of Allergy and Clinical Immunology - April 16, 2021 Category: Allergy & Immunology Authors: Steven G. Kelsen, Ioana O. Agache, Weily Soong, Elliot Israel, Geoffrey L. Chupp, Dorothy S. Cheung, Wiebke Theess, Xiaoying Yang, Tracy L. Staton, David F. Choy, Alice Fong, Ajit Dash, Michael Dolton, Rajita Pappu, Christopher E. Brightling Source Type: research